CL2018001395A1 - Composiciones farmacéuticas que comprenden amida de levodopa y sus uso - Google Patents

Composiciones farmacéuticas que comprenden amida de levodopa y sus uso

Info

Publication number
CL2018001395A1
CL2018001395A1 CL2018001395A CL2018001395A CL2018001395A1 CL 2018001395 A1 CL2018001395 A1 CL 2018001395A1 CL 2018001395 A CL2018001395 A CL 2018001395A CL 2018001395 A CL2018001395 A CL 2018001395A CL 2018001395 A1 CL2018001395 A1 CL 2018001395A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
levodopa
amide
levodopa amide
normation
Prior art date
Application number
CL2018001395A
Other languages
English (en)
Inventor
Oron Yacoby-Zeevi
Mara Nemes
Eduardo Zwoznik
Irena Vainshtok
Einat Sela
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of CL2018001395A1 publication Critical patent/CL2018001395A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN DESVELA DISTINTAS COMPOSICIONES FARMACÉUTICAS ACUOSAS QUE COMPRENDEN UN COMPUESTO DE AMIDA DE LEVODOPA O UNA DE SUS SALES, QUE SON ESTABLES DURANTE AL MENOS 24 HORAS A TEMPERATURA AMBIENTE Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES O TRASTORNOS CARACTERIZADOS POR  NEURODEGENERACIÓN Y/O NIVELES REDUCIDOS DE DOPAMINA EN EL CEREBRO, POR EJEMPLO, ENFERMEDAD DE PARKINSON.
CL2018001395A 2015-11-24 2018-05-24 Composiciones farmacéuticas que comprenden amida de levodopa y sus uso CL2018001395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562259324P 2015-11-24 2015-11-24

Publications (1)

Publication Number Publication Date
CL2018001395A1 true CL2018001395A1 (es) 2018-10-12

Family

ID=57590758

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001395A CL2018001395A1 (es) 2015-11-24 2018-05-24 Composiciones farmacéuticas que comprenden amida de levodopa y sus uso

Country Status (13)

Country Link
US (1) US20170296491A1 (es)
EP (1) EP3380076A2 (es)
JP (1) JP2018535230A (es)
CN (1) CN108495617A (es)
AU (1) AU2016358511A1 (es)
BR (1) BR112018010564A2 (es)
CA (1) CA3006028A1 (es)
CL (1) CL2018001395A1 (es)
IL (1) IL259484A (es)
RU (1) RU2018119194A (es)
SG (1) SG11201804395PA (es)
WO (1) WO2017090039A2 (es)
ZA (1) ZA201803485B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231716T1 (hr) 2014-03-13 2024-03-15 Neuroderm Ltd. Pripravci inhibitora dopa dekarboksilaze
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
AR112472A1 (es) 2017-08-21 2019-10-30 Neuroderm Ltd Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
AR112683A1 (es) 2017-08-21 2019-11-27 Neuroderm Ltd Forma cristalina de base libre de levodopa, su sal de adición y composición farmaceutica que la comprende
WO2019038638A1 (en) 2017-08-21 2019-02-28 Neuroderm Ltd PROCESS FOR PREPARING AMIDE OF PURIFIED LEVODOPA
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
WO2020178810A1 (en) * 2019-03-04 2020-09-10 Neuroderm, Ltd. Pharmaceutical compositions comprising levodopa amide derivatives and uses thereof
WO2021044420A1 (en) * 2019-09-05 2021-03-11 Neuroderm, Ltd. Liquid compositions comprising a levodopa amino acid conjugate and uses thereof
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
LT2432454T (lt) 2009-05-19 2017-07-10 Neuroderm Ltd Kompozicijos, skirtos nepertraukiamam dopa dekarboksilazės inhibitorių vartojimui
WO2012079072A2 (en) * 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
WO2013184646A2 (en) * 2012-06-05 2013-12-12 Synagile Corporation Dosing regimens for subcutaneously infusible acidic compositions

Also Published As

Publication number Publication date
WO2017090039A3 (en) 2017-08-31
IL259484A (en) 2018-07-31
SG11201804395PA (en) 2018-06-28
US20170296491A1 (en) 2017-10-19
CN108495617A (zh) 2018-09-04
RU2018119194A (ru) 2019-12-25
JP2018535230A (ja) 2018-11-29
RU2018119194A3 (es) 2020-04-20
CA3006028A1 (en) 2017-06-01
BR112018010564A2 (pt) 2018-11-21
AU2016358511A1 (en) 2018-06-21
ZA201803485B (en) 2019-08-28
EP3380076A2 (en) 2018-10-03
WO2017090039A2 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
CL2018001395A1 (es) Composiciones farmacéuticas que comprenden amida de levodopa y sus uso
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
ECSP20030074A (es) Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2020000383A1 (es) Composiciones de aminoácidos para el tratamiento de lesión neuronal.
CY1120348T1 (el) Αμiδια ετεροαρυλιου ως αναστολεις της συσσωματωσης πρωτεϊνων
UY32123A (es) Derivados de n - (sustituido) - 4 - (but-2-iniloxi) - benzamida, sus racematos, diastereòmeros, enantiòmeros y las sales de los mismos y aplicaciones
CR20160348A (es) Compuestos
CL2020000382A1 (es) Composiciones de aminoácidos para el tratamiento de enfermedad hepática.
UY36125A (es) ?Composiciones plaguicidas y métodos relacionados?.
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112016021034A8 (pt) composição farmacêutica, uso da mesma e kit
BR112019009172A2 (pt) formulações para radioterapia e diagnóstico por imagem.
DOP2017000260A (es) Piroglutamato de vortioxetina
AR112472A1 (es) Forma de sales cristalinas de amida de levodopa y métodos para elaborarlas y usarlas
DK3463351T3 (da) Behandling til parkinsons sygdom
PL3377909T3 (pl) Laktoferyna do zastosowania w diagnozowaniu lub prognozowaniu choroby Alzheimera
BR112015003957A2 (pt) alfa-1-microglobulina para uso no tratamento de doenças relacionadas com a mitocôndria
BR112018072342A2 (pt) métodos e dispositivos para preparação de agentes de contraste de ultrassom
DOP2018000060A (es) Derivado de oxima de cromona penetrante del cerebro para la terapia de disquinesia inducida por levopoda
SV2016005305A (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
AR106313A1 (es) Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson
CY1119674T1 (el) Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad)
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas